The pharmacological inhibition of c-Abl is also emerging as an attractive therapeutic strategy, as it was found to be neuroprotective in animal models of PD (Ko et al., 2010; Imam et al., 2011, 2013; Hebron et al., 2013a; Mahul-Mellier et al., 2014), by promoting aSyn degradation (Hebron et al., 2013a,b; Mahul-Mellier et al., 2014). Here, ABL1 is linked to Parkinson disease.